- ProMIS Neurosciences Inc. (PMN) received **DSMB approval** to advance its PMN310 Alzheimer's trial to the **third and final dose escalation cohort**.  **[1374339_0001558370-25-011845_pmn-20250903xex99d1.htm:0]** **[1374339_0001558370-25-011845_pmn-20250903x8k.htm:1]** **[1374339_0001558370-25-011845_pmn-20250903x8k.htm:2]** 
- The Phase 1b PRECISE-AD trial has seen **no cases of amyloid-related imaging abnormalities (ARIA)** observed to date, with enrollment and dosing for Cohort 3 now underway.  **[1374339_0001558370-25-011845_pmn-20250903xex99d1.htm:0]** **[1374339_0001558370-25-011845_pmn-20250903x8k.htm:2]** 
- The trial, expected to enroll **128 patients**, remains on track to report **6-month interim data in Q2 2026** and **final 12-month top-line results in Q4 2026**.  **[1374339_0001558370-25-011845_pmn-20250903xex99d1.htm:0]** **[1374339_0001558370-25-011845_pmn-20250903x8k.htm:2]** 
- PMN310 was granted **Fast Track designation** by the U.S. Food and Drug Administration in **July 2025**.  **[1374339_0001558370-25-011845_pmn-20250903xex99d1.htm:1]**

ProMIS Neurosciences (PMN)